EBV+ CNS LYMPHOMAS HAVE A DISTINCTIVE TUMOR MICROENVIRONMENT AND GENETIC PROFILE, WHICH IS AMENABLE TO COMBINATION 3RD PARTY EBV‐SPECIFIC CTL AND IBRUTINIB THERAPY. (12th June 2019) - Gandhi, M.K.; Hoang, T.; Tobin, J.W.; Law, S.C.; Talaulikar, D.; Jain, S.; Vari, F.; Murigneux, V.; Fink, L.; Gunawardana, J.; Gould, C.; Oey, H.; et al.